CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 05:43:35 2024-06-04 am EDT | ||
| 2.105 EUR | +2.93% |
|
| Current month | +2.00% | ||
| 1 month | +114.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 2.105 | +2.93% |
| 24-06-03 | 2.045 | +2.00% |
| 24-05-31 | 2.005 | +6.08% |
| 24-05-30 | 1.89 | +5.88% |
| 24-05-29 | 1.785 | -6.05% |
Real-time Euronext Paris
Last update June 04, 2024 at 05:43 am EDT
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WH9LB | |
| ISIN | NLBNPNL2HAS7 |
| Date issued | 2023-08-24 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.03 € |
|---|---|
| Lowest since issue | 0.215 € |
| Spread | 0.05 € |
| Spread % | 2.37% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.2
DKK
Spread / Average Target
-0.72%
- Stock Market
- Certificates
- WH9LB Certificat
